Understand the source comparison
How to Lose Visceral Fat with Peptides: Protocol Comparison
GLP-1 Monotherapy Semaglutide 2.4mg weekly or Tirzepatide 15mg weekly Insulin modulation, reduced lipid deposition 24–72 weeks 15–22% (MRI-measured VAT) Individuals with high postprandial insulin, metabolic syndrome, or those who need appetite control alongsid
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- GLP-1 Monotherapy
- Semaglutide 2.4mg weekly or Tirzepatide 15mg weekly
- Insulin modulation, reduced lipid deposition
- 24–72 weeks
- 15–22% (MRI-measured VAT)
- Individuals with high postprandial insulin, metabolic syndrome, or those who need appetite control alongside fat loss
- GH Secretagogue Protocol
- CJC-1295 (no DAC) 100mcg + Ipamorelin 100mcg daily, fasted
- GH-mediated lipolysis via hormone-sensitive lipase
- 12–24 weeks
- 10–14% (DEXA-measured VAT)
- Lean individuals with isolated visceral fat, those seeking muscle preservation during fat loss
- Dual-Action (GLP-1 + GH)
- Semaglutide weekly + CJC/Ipamorelin daily
- Prevents deposition + mobilises existing fat
- 16–32 weeks
- 20–28% (combined MRI and DEXA studies)
- Individuals with significant visceral adiposity (>100cm² VAT area on MRI), insulin resistance, and lean mass preservation goals
- Metabolic Modulator Stack
- Tesofensine 0.5mg daily + AOD-9604 1mg daily
- Thermogenesis + direct lipolysis without GH suppression
- 12–20 weeks
- 12–18% (waist circumference and MRI)
- Research contexts exploring non-GLP-1, non-GH pathways; those with GH contraindications